Inventors list |
Assignees list |
Classification tree browser |
Top 100 Inventors |
Top 100 Assignees |
Ling Wang
Ling Wang, San Jose, CA US
| Patent application number | Description | Published |
|---|---|---|
| 20090006331 | ENTITY-BASED BUSINESS INTELLIGENCE - A method is disclosed for conducting a query to transform data in a pre-existing database, the method comprising: collecting database information from the pre-existing database, the database information including inconsistent dimensional tables and fact tables; running an entity discovery process on the inconsistent dimensional tables and the fact tables to produce entity mapping tables; using the entity mapping tables to resolve the inconsistent dimensional tables into resolved dimensional tables; and running the query on a resolved database to obtain a query result, the resolved database including the resolved dimensional table. | 01-01-2009 |
| 20090006349 | ENTITY-BASED BUSINESS INTELLIGENCE - A method is disclosed for conducting a query to transform data in a pre-existing database, the method comprising: collecting database information from the pre-existing database, the database information including inconsistent dimensional tables and fact tables; running an entity discovery process on the inconsistent dimensional tables and the fact tables to produce entity mapping tables; using the entity mapping tables to resolve the inconsistent dimensional tables into resolved dimensional tables; and running the query on a resolved database to obtain a query result, the resolved database including the resolved dimensional table. | 01-01-2009 |
| 20110079918 | PLASMA-BASED ORGANIC MASK REMOVAL WITH SILICON FLUORIDE - Removal of organic mask material from an etched dielectric film with an etchant gas mixture including silicon fluoride (SiF | 04-07-2011 |
Ling Wang, Jiangsu Province CN
| Patent application number | Description | Published |
|---|---|---|
| 20110012581 | BANDGAP CIRCUIT HAVING A ZERO TEMPERATURE COEFFICIENT - A bandgap circuit is provided, which includes a current source, a voltage boost circuit, a voltage input circuit, a voltage equalizer circuit, and a voltage output circuit. The current source provides a first current, a second current, and a third current, which are equal to one another. The voltage boost circuit provides a boost voltage by a single current path. The voltage input circuit receives the first and the second currents, and provides a first input voltage and a second input voltage based on the boost voltage. The voltage equalizer circuit receives the first and the second input voltages and equalize the two input voltages. The voltage output circuit provides a bandgap reference voltage according to the third current. | 01-20-2011 |
Ling Wang, Vancouver CA
| Patent application number | Description | Published |
|---|---|---|
| 20080312148 | RECOMBINANT HUMAN INTERFERON-LIKE PROTEINS - This application relates to recombinant human interferon-like proteins. In one embodiment a recombinant protein created by gene shuffling technology is described having enhanced anti-viral and anti-proliferative activities in comparison to naturally occurring human interferon alpha 2b (HuIFN-α2b). The invention encompasses a polynucleotide encoding the protein and recombinant vectors and host cells comprising the polynucleotide. Preferably the polynucleotide is selected from the group of polynucleotides each having a sequence at least 93% identical to SEQ ID: No. 1 and the protein is selected from the group of proteins each having an amino acid sequence at least 85% identical to SEQ ID No: 2. The proteins and compositions comprising the proteins can be used for treatment of conditions responsive to interferon therapy, such as viral diseases and cancer. | 12-18-2008 |
| 20100099612 | RECOMBINANT HUMAN INTERFERON-LIKE PROTEINS - This application relates to recombinant human interferon-like proteins. In one embodiment a recombinant protein created by gene shuffling technology is described having enhanced anti-viral and anti-proliferative activities in comparison to naturally occurring human interferon alpha 2b (HuIFN-α2b). The invention encompasses a polynucleotide encoding the protein and recombinant vectors and host cells comprising the polynucleotide. Preferably the polynucleotide is selected from the group of polynucleotides each having a sequence at least 93% identical to SEQ ID: No. 1 and the protein is selected from the group of proteins each having an amino acid sequence at least 85% identical to SEQ ID No: 2. The proteins and compositions comprising the proteins can be used for treatment of conditions responsive to interferon therapy, such as viral diseases and cancer. | 04-22-2010 |
| 20100129904 | RECOMBINANT HUMAN INTERFERON-LIKE PROTEINS - This application relates to recombinant human interferon-like proteins. In one embodiment a recombinant protein created by gene shuffling technology is described having enhanced anti-viral and anti-proliferative activities in comparison to naturally occurring human interferon alpha 2b (HuIFN-α2b). The invention encompasses a polynucleotide encoding the protein and recombinant vectors and host cells comprising the polynucleotide. Preferably the polynucleotide is selected from the group of polynucleotides each having a sequence at least 93% identical to SEQ ID: No. 1 and the protein is selected from the group of proteins each having an amino acid sequence at least 85% identical to SEQ ID No: 2. The proteins and compositions comprising the proteins can be used for treatment of conditions responsive to interferon therapy, such as viral diseases and cancer. | 05-27-2010 |
| 20100303759 | RECOMBINANT HUMAN INTERFERON-LIKE PROTEINS - This application relates to recombinant human interferon-like proteins. In one embodiment a recombinant protein created by gene shuffling technology is described having enhanced anti-viral and anti-proliferative activities in comparison to naturally occurring human interferon alpha 2b (HuIFN-α2b). The invention encompasses a polynucleotide encoding the protein and recombinant vectors and host cells comprising the polynucleotide. Preferably the polynucleotide is selected from the group of polynucleotides each having a sequence at least 93% identical to SEQ ID: No. 1 and the protein is selected from the group of proteins each having an amino acid sequence at least 85% identical to SEQ ID No: 2. The proteins and compositions comprising the proteins can be used for treatment of conditions responsive to interferon therapy, such as viral diseases and cancer. | 12-02-2010 |
Ling Wang, Union City, CA US
| Patent application number | Description | Published |
|---|---|---|
| 20100267671 | COMPOSITIONS AND METHODS FOR APOPTOSIS MODULATORS - The present invention includes and relates generally to compounds which modulate apoptosis in cells. The present invention also provides pharmaceutical compositions containing these compounds, methods of making these compounds, and methods of using these compounds and pharmaceutical compositions for treatment of diseases associated with irregular apoptosis in cells. | 10-21-2010 |
Ling Wang, Seattle, WA US
| Patent application number | Description | Published |
|---|---|---|
| 20100216853 | Methods and Compositions for Modulating P300/CBP Activity - The present invention relates to a method for identifying compounds that modulate the activity of p300/CBP. Compounds of the invention are identified by designing or screening for a compound which binds to at least one amino acid residue of the newly identified lysine-CoA inhibitor binding site, L1 loop, electronegative pocket, or electronegative groove of the HAT domain of p300/CBP and testing the compound for its ability to modulate the activity of p300/CBP. Compositions and methods for preventing or treating diseases or disorders associated with p300/CBP are also provided as is a method for producing a semi-synthetic HAT domain. | 08-26-2010 |
Ling Wang US
| Patent application number | Description | Published |
|---|---|---|
| 20100098716 | RECOMBINANT HUMAN EPO-FC FUSION PROTEINS WITH PROLONGED HALF-LIFE AND ENHANCED ERYTHROPOIETIC ACTIVITY IN VIVO - A recombinant fusion protein comprising a human erythropoietin peptide portion linked to an immunoglobulin peptide portion is described. The fusion protein has a prolonged half-life in vivo in comparison to naturally occurring or recombinant native human erythropoietin. In one embodiment of the invention, the protein has a half-life in vivo at least three fold higher than native human erythropoietin. The fusion protein also exhibits enhanced erythropoietic bioactivity in comparison to native human erythropoietin. In one embodiment, the fusion protein comprises the complete peptide sequence of a human erythropoietin (EPO) molecule and the peptide sequence of an Fc fragment of human immunoglobulin IgG1. The Fc fragment in the fusion protein includes the hinge region, CH2 and CH3 domains of human immunoglobulin IgG1. The EPO molecule may be linked directly to the Fc fragment to avoid extraneous peptide linkers and lessen the risk of an immunogenic response when administered in vivo. In one embodiment the hinge region is a human Fc fragment variant having a non-cysteine residue at amino acid 6. The invention also relates to nucleic acid and amino acid sequences encoding the fusion protein and transfected cell lines and methods for producing the fusion protein. The invention further includes pharmaceutical compositions comprising the fusion protein and methods of using the fusion protein and/or the pharmaceutical compositions, for example to stimulate erythropoiesis in subjects in need of therapy. | 04-22-2010 |
| 20100099145 | RECOMBINANT HUMAN EPO-FC FUSION PROTEINS WITH PROLONGED HALF-LIFE AND ENHANCED ERYTHROPOIETIC ACTIVITY IN VIVO - A recombinant fusion protein comprising a human erythropoietin peptide portion linked to an immunoglobulin peptide portion is described. The fusion protein has a prolonged half-life in vivo in comparison to naturally occurring or recombinant native human erythropoietin. In one embodiment of the invention, the protein has a half-life in vivo at least three fold higher than native human erythropoietin. The fusion protein also exhibits enhanced erythropoietic bioactivity in comparison to native human erythropoietin. In one embodiment, the fusion protein comprises the complete peptide sequence of a human erythropoietin (EPO) molecule and the peptide sequence of an Fc fragment of human immunoglobulin IgG1. The Fc fragment in the fusion protein includes the hinge region, CH2 and CH3 domains of human immunoglobulin IgG1. The EPO molecule may be linked directly to the Fc fragment to avoid extraneous peptide linkers and lessen the risk of an immunogenic response when administered in vivo. In one embodiment the hinge region is a human Fc fragment variant having a non-cysteine residue at amino acid 6. The invention also relates to nucleic acid and amino acid sequences encoding the fusion protein and transfected cell lines and methods for producing the fusion protein. The invention further includes pharmaceutical compositions comprising the fusion protein and methods of using the fusion protein and/or the pharmaceutical compositions, for example to stimulate erythropoiesis in subjects in need of therapy. | 04-22-2010 |
Ling Wang, Chicago, IL US
| Patent application number | Description | Published |
|---|---|---|
| 20080218087 | Lighting Commissioning Device and Method - A lighting commissioning device and method including a lighting commissioning device for commissioning of a lighting device in a lighting system, the lighting commissioning device including an indication detector | 09-11-2008 |
| 20090150004 | WIRELESS BUILDING AUTOMATION AND CONTROL NETWORK - A network ( | 06-11-2009 |
Ling Wang, Millwood, NY US
| Patent application number | Description | Published |
|---|---|---|
| 20080265782 | Lighting System Control Device Charging System and Method - A lighting system control device charging system and method including a control device charged from a light source in a lighting system, including control photovoltaic cell | 10-30-2008 |
Ling Wang, Beijing CN
| Patent application number | Description | Published |
|---|---|---|
| 20110224300 | USE OF POTASSIUM 2-(a- HYDROXYPENTYL) BENZOATE IN THE MANUFACTURE OF MEDICAMENTS FOR PREVENTING AND/OR TREATING SENILE DEMENTIA - The present invention discloses the use of potassium 2-(α-hydroxypentyl) benzoate in the manufacture of medicaments for preventing, relieving or treating senile dementia diseases or symptom, and for relieving oxidative stress injury in brain tissue, increasing neural function of choline, protecting neuron and/or raising the content of brain nerve growth factor. The present invention also discloses a pharmaceutical composition comprising potassium 2-(α-hydroxypentyl) benzoate in prophylactically or therapeutically effective dose, optionally, a pharmaceutically acceptable carrier and/or adjuvant. | 09-15-2011 |
Ling Wang, Shandong CN
| Patent application number | Description | Published |
|---|---|---|
| 20110288191 | MACROPOROUS ABSORBENT RESIN FOR EXTRACTING CEPHALOSPORIN C AND METHOD OF PREPARATION - The invention relates to macroporous absorbent resin special for extracting cephalosporin C and process for preparation. Specific surface area of such kinds of adsorbent resins is around 1000-2000 m | 11-24-2011 |
Ling Wang, San Ardo Union City, CA US
| Patent application number | Description | Published |
|---|---|---|
| 20110301133 | COMPOSITIONS OF PROTEIN RECEPTOR TYROSINE KINASE INHIBITORS - The present invention relates to novel synthetic substituted heterocyclic compounds and pharmaceutical compositions containing the same that are capable of inhibiting or antagonizing a family of receptor tyrosine kinases, Tropomysosin Related Kinases (Trk), in particular the nerve growth factor (NGF) receptor, TrkA. The invention further concerns the use of such compounds in the treatment and/or prevention of pain, cancer, restenosis, atherosclerosis, psoriasis, thrombosis, or a disease, disorder or injury relating to dysmyelination or demyelination or the disease or disorder associated with abnormal activities of NGF receptor TrkA. | 12-08-2011 |